Open AccessEfficacy of stem cell in improvement of left ventricular function in acute myocardial infarction - MI3 Trial
Author(s) -
Velu Nair,
Hemant Madan,
Sunil Sofat,
Prosenjit Ganguli,
M J Jacob,
R. Κ. Datta,
Prashant Bharadwaj,
Ritam Sarkar,
A J Pandit,
Soniya Nityanand,
Pravin K. Goel,
Naveen Garg,
Sanjay Gambhir,
Paul V. George,
Sunil Chandy,
Vikram Mathews,
Oommen K George,
Talwar Kk,
Ajay Bahl,
Neelam Marwah,
A Bhatacharya,
Balram Bhargava,
Balram Airan,
Sujata Mohanty,
Chetan Patel,
Alka Sharma,
Shinjini Bhatnagar,
Abhinandan Mondal,
Jacob Jose,
Anjili Srivastava,
Mi Trial
Publication year - 2015
Publication title -
indian journal of medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.578
H-Index - 87
ISSN - 0971-5916
DOI - 10.4103/0971-5916.164245
Subject(s) - ejection fraction , medicine , myocardial infarction , cardiology , conventional pci , percutaneous coronary intervention , randomized controlled trial , stem cell therapy , heart failure , transplantation
Acute myocardial infarction (AMI) is characterized by irreparable and irreversible loss of cardiac myocytes. Despite major advances in the management of AMI, a large number of patients are left with reduced left ventricular ejection fraction (LVEF), which is a major determinant of short and long term morbidity and mortality. A review of 33 randomized control trials has shown varying improvement in left ventricular (LV) function in patients receiving stem cells compared to standard medical therapy. Most trials had small sample size and were underpowered. This phase III prospective, open labelled, randomized multicenteric trial was undertaken to evaluate the efficacy in improving the LVEF over a period of six months, after injecting a predefined dose of 5-10 × 10 [8] autologous mononuclear cells (MNC) by intra-coronary route, in patients, one to three weeks post ST elevation AMI, in addition to the standard medical therapy.